FDA approves ‘robust’ dementia drug that slows cognitive declineBy Marc Lallanilla
June 12, 2023
A Food and Drug Administration panel has unanimously approved the use of lecanemab to slow the progression of Alzheimer’s disease.
The expert panel described the results of a clinical trial of lecanemab as “robust” and “clear and consistent,” according to Medscape.
Their approval means the medication, which is sold under the brand name Leqembi, should get full FDA approval by July 6, giving hope to the 6.5 million people affected by Alzheimer’s disease, a brain disorder that gets worse over time.
But even though the FDA approved lecanemab through an accelerated approval process, the Centers for Medicare and Medicaid Services — which controls Medicare — will only cover the drug for patients who enroll in a national registry.
That registry does not yet exist, and it’s still unknown when or how patients, their doctors or caregivers would sign up for it.
* * *
Source:
https://nypost.com/2023/06/12/fda-approves-dementia-drug-that-slows-cognitive-decline/